Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Medclair ABNGM:MCLR +1.76%71 EV-to-OCF is 183.70 as of Aug. 30, 2026. GuruFocus rates NGM:MCLR with a GF Score™ of 71/100 and a GF Value™ of kr2.21 (Significantly Overvalued). The stock has 2 warning signs investors should review. Among 851 Medical Devices & Instruments companies, Medclair AB ranks worse than 97.77% on this metric.
EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, Medclair AB's Enterprise Value is kr263.60 Mil.
Medclair AB's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 was kr1.44 Mil. Therefore, Medclair AB's EV-to-OCF for today is 183.70.
The historical rank and industry rank for Medclair AB's EV-to-OCF or its related term are showing as below:
NGM:MCLR'
s EV-to-OCF Range Over the Past 10 Years
Min: -279.79 Med: -20.89 Max: 195.28
Current: 183.7
During the past 11 years, the highest EV-to-OCF of Medclair AB was 195.28. The lowest was -279.79. And the median was -20.89.
NGM:MCLR's EV-to-OCF is ranked worse than 97.77% of 851
companies
in the Medical Devices & Instruments industry
Industry Median: 7.91
vs NGM:MCLR: 183.70
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Medclair AB's PE Ratio (TTM) for today is calculated as:
Medclair AB's share price for today is kr2.89.
Medclair AB's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr0.005.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Medclair AB EV-to-OCF Related Terms
Medclair AB EV-to-OCF Historical Data
* Premium members only.
The historical data trend for Medclair AB's EV-to-OCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Medclair AB's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Medclair AB EV-to-OCF vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Medclair AB's EV-to-OCF distribution charts can be found below:
* The bar in red indicates where Medclair AB's EV-to-OCF falls into.
Medclair AB's current Enterprise Value is kr263.60 Mil.
Medclair AB's Cash Flow from Operations for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was kr1.44 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Medclair AB (NGM:MCLR) has a EV-to-OCF of 183.70 as of Aug. 30, 2026. According to the industry distribution chart, Medclair AB ranks #832 out of 851 companies in the Medical Devices & Instruments industry, placing it in the top 97.8%.
Is Medclair AB's EV-to-OCF too high?
Medclair AB's current EV-to-OCF is 183.70. The Medical Devices & Instruments industry median EV-to-OCF is 7.91. Medclair AB's value of 183.70 is 2222.4% above this industry median. Based on the distribution chart, Medclair AB ranks #832 out of 851 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Medclair AB has a GF Score™ of 71/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Medclair AB's EV-to-OCF compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Medclair AB ranks #832 out of 851 companies for EV-to-OCF. This places Medclair AB in the lower half of its industry. The industry median EV-to-OCF is 7.91. Medclair AB's value of 183.70 is 2222.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Medical Devices & Instruments company?
The median EV-to-OCF among Medical Devices & Instruments companies is 7.91, based on 851 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Medclair AB's current EV-to-OCF of 183.70 is 2222.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Medical Devices & Instruments industry, the median EV-to-OCF is 7.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Medclair AB's current EV-to-OCF is 183.70. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medclair AB stock overvalued right now?
Based on GuruFocus' analysis, Medclair AB (NGM:MCLR) is currently considered Significantly Overvalued. The stock's GF Value™ is kr2.21, compared to a current price of kr2.89 — trading 30.8% above its estimated fair value. The current EV-to-OCF is 183.70 and 2222.4% above the Medical Devices & Instruments industry median of 7.91. Medclair AB's overall GF Score™ is 71/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For Medclair AB (NGM:MCLR), the current EV-to-OCF is 183.70 as of Aug. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Medclair AB (NGM:MCLR) Overvalued in 2026?
Based on GuruFocus' analysis, Medclair AB stock appears to be overvalued.
The current stock price of kr2.89 is trading 30.8% above its estimated GF Value™ of kr2.21.
GuruFocus considers Medclair AB to be Significantly Overvalued.
Key valuation signals for NGM:MCLR:
EV-to-OCF: 183.70
GF Value™: kr2.21 vs. price of kr2.89 (30.8% above fair value)
Industry Position: 2222.4% above the Medical Devices & Instruments median (#832 of 851)
No single metric tells the full story. See the NGM:MCLR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Medclair AB operates in healthcare industry. The company has two units: Central Destruction Unit (CDU) and Mobile Destruction Unit (MDU) decomposes the nitrous oxide entering the unit, transforming it to nitrogen (N2) och oxygen (O2). It also provide solutions for various N2O methods such as double mask, single mask, mouthpiece, or free flow, which ensures a safe work environment for healthcare professionals.
71GF Score
Get the complete analysis for NGM:MCLR
EV-to-OCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NGM:MCLR has been successfully added to your 
